Get Our Free Research Email
March 14-18 - American Association of Orthopaedic Medicine Annual Meeting 2017
March 14-December 31 - Canaccord Genuity Musculoskeletal ConferenceComplete Calendar »
Complete Calendar »
Five-year Distribution and Licensing Agreement Executed between CREASPINE SAS and SCIENT'X SA BY EDITOR, OCTOBER 1, 2010
CREASPINE SAS and SCIENT'X SA, a wholly owned subsidiary of Alphatec Holdings, Inc., today announce they have entered into a five-year exclusive worldwide Distribution and Licensing Agreement. Under the terms of the Agreement, CREASPINE will manufacture and provide to SCIENT'X and its affiliates an innovative interbody fusion device marketed under the name ISOFORM.
ISOFORM has received CE mark approval and will be deployed first in key geographies, and is expected to deliver a genuinely elegant and original fusion solution in the Interbody Devices segment.
Philippe Jenny, M.D., CREASPINE's President, commented: "We are very happy for CREASPINE to have signed such an agreement with SCIENT'X, as they are the historical leader in Interbody Device solutions. It is a key milestone for our organization as it demonstrates the effectiveness and value add of our business model to provide innovative solutions to spine surgeons and the industry."
Dirk Kuyper, President and Chief Executive Officer of ALPHATEC SPINE commented: "I am delighted that SCIENT'X has established a partnership with CREASPINE to distribute the ISOFORM interbody fusion spacer globally. I believe this is an extremely exciting technology for our Aging Spine product portfolio that will be a welcome addition to our international product offering."
Franck Tricot, CREASPINE's Director of Business Development, concluded: "I am thrilled that SCIENT'X chose us as provider of innovation in a well-established market segment. With the global reach of SCIENT'X and ALPHATEC SPINE, we have confidence in their ability to successfully represent our proprietary technology in every key international market."
The Agreement also provides CREASPINE and SCIENT'X with additional business and technology development opportunities.